Patient outcomes following a response biomarker-guided approach to treatment using 177Lu-PSMA-I&T in men with metastatic castrate-resistant prostate cancer (Re-SPECT)

Patient outcomes following a response biomarker-guided approach to treatment using 177Lu-PSMA-I&T in men with metastatic castrate-resistant prostate cancer (Re-SPECT)

Background: 177 LuPSMA is an effective treatment in metastatic castrate-resistant prostate cancer with trials adopting a standardised dose interval. Adjusting treatment intervals utilising early response biomarkers may improve patient outcomes. Objective: This study evaluated progression-free surviv...

Full description

Bibliographic Details
Main Authors: Louise Emmett, Nikeith John, Sarennya Pathmanandavel, William Counter, Maria Ayers, Shikha Sharma, Shikha Agrawal, Aron Poole, Elizabeth Hovey, Ganes Pranavan, Craig Gedye, Girish Mallesara, Alex Guminski, Adrian Lee, Martin R. Stockler, Adam Hickey, Peter Eu, Anthony M. Joshua, Megan Crumbaker, Andrew Nguyen
Format: Article
Language:English
Published: SAGE Publishing 2023-03-01
Series:Therapeutic Advances in Medical Oncology
Online Access:https://doi.org/10.1177/17588359231156392

Internet

https://doi.org/10.1177/17588359231156392

Similar Items